Want to see CADL full AI Analyst Report?
Top Page
Candel Therapeutics
(NASDAQ:CADL)
Select Model
Select Model
Rating:56Neutral
Price Target:
$9.50
▲(49.14% Upside)
Action:Reiterated
Date:06/25/26
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and significant cash burn) despite a stronger, low-debt balance sheet. Technicals are a notable positive with an uptrend and supportive momentum. Valuation is less supportive due to negative earnings and no dividend, while corporate updates are modestly constructive but not decisive for near-term fundamentals.
Positive Factors
Balance sheet strength
A materially stronger equity base and very low leverage give Candel financial flexibility to fund clinical programs and operate over coming months without immediate debt pressure. This reduces short-term liquidation risk and supports strategic options like partnerships or milestone-driven financings.
Negative Factors
Pre-revenue model
With no product revenue, the business must rely on external financing or partnership deals to fund operations. This structural lack of recurring cash inflows amplifies dependency on clinical milestones and raises execution risk for sustaining R&D and trials over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
A materially stronger equity base and very low leverage give Candel financial flexibility to fund clinical programs and operate over coming months without immediate debt pressure. This reduces short-term liquidation risk and supports strategic options like partnerships or milestone-driven financings.
Read all positive factors
Candel Therapeutics (CADL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$717.32M
Dividend YieldN/A
Average Volume (3M)2.28M
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS Growth26.28%
CountryUS
Employees38
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.98
Shares Outstanding73,270,240
10 Day Avg. Volume2,306,496
30 Day Avg. Volume2,278,531
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.76
Price to Sales (P/S)0.00
P/FCF Ratio-7.69
Enterprise Value/Market Cap0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.88
Forecast
1Y Price Target
$20.60Price Target Upside223.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.94
Revenue Forecast (FY)N/A
Candel Therapeutics Business Overview & Revenue Model
Company Description
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical t...
How the Company Makes Money
Candel Therapeutics is a clinical-stage biotechnology company and, based on publicly available information, it does not have approved products and therefore does not generate recurring product sales revenue. Its revenue, when present, is primarily...
Candel Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 125.00K | 125.00K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 125.00K | 125.00K |
| EBITDA | -50.30M | -35.22M | -52.10M | -34.38M | -16.31M | -24.42M |
| Net Income | -54.42M | -38.18M | -55.18M | -37.94M | -18.79M | -36.12M |
Balance Sheet | ||||||
| Total Assets | 201.92M | 125.19M | 106.87M | 41.20M | 78.52M | 89.20M |
| Cash, Cash Equivalents and Short-Term Investments | 194.83M | 119.73M | 102.65M | 35.41M | 70.06M | 82.64M |
| Total Debt | 1.80M | 1.90M | 13.47M | 22.76M | 22.80M | 560.00K |
| Total Liabilities | 63.89M | 73.27M | 40.54M | 28.46M | 30.80M | 25.07M |
| Stockholders Equity | 138.03M | 51.92M | 66.33M | 12.74M | 47.71M | 64.14M |
Cash Flow | ||||||
| Free Cash Flow | -48.99M | -38.90M | -27.04M | -34.70M | -32.72M | -24.05M |
| Operating Cash Flow | -47.73M | -38.31M | -27.02M | -34.24M | -31.42M | -22.22M |
| Investing Cash Flow | -1.23M | -560.00K | -16.00K | -280.00K | -1.30M | -1.83M |
| Financing Cash Flow | 151.78M | 56.10M | 94.28M | -121.00K | 19.97M | 71.80M |
Candel Therapeutics Technical Analysis
Positive
6.37
Price Trends
7.96
Positive
6.56
Positive
6.00
Positive
Market Momentum
0.40
Negative
68.15
Neutral
88.92
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CADL, the sentiment is Positive. The current price of 6.37 is below the 20-day moving average (MA) of 8.68, below the 50-day MA of 7.96, and above the 200-day MA of 6.00, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 68.15 is Neutral, neither overbought nor oversold. The STOCH value of 88.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CADL.
Candel Therapeutics Risk Analysis
Candel Therapeutics disclosed 92 risk factors in its most recent earnings report. Candel Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Candel Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $717.32M | -10.54 | -60.42% | ― | ― | 26.28% | |
55 Neutral | $1.88B | -12.85 | -40.99% | ― | -73.07% | -2335.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $191.07M | -1.36 | -2781.56% | ― | 289.94% | 16.60% | |
49 Neutral | $191.45M | ― | -67.65% | ― | 74.84% | 99.51% | |
47 Neutral | $186.14M | -1.73 | -47.35% | ― | -46.21% | 23.81% | |
46 Neutral | $1.39B | -11.38 | -563.89% | ― | 550.00% | -107.04% |
* Healthcare Sector Average
CADL
Candel Therapeutics
10.36
5.30
104.74%
TNXP
Tonix Pharma
12.75
-23.23
-64.56%
QSI
Quantum-Si
0.89
-1.07
-54.69%
HUMA
Humacyte
0.80
-1.29
-61.82%
GLUE
Monte Rosa Therapeutics
23.90
19.39
429.93%
INBX
Inhibrx Biosciences Inc
95.50
81.23
569.24%
Candel Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Candel Therapeutics Stockholders Approve Directors and Auditor
Positive
Jun 24, 2026
Candel Therapeutics, Inc. held its Annual Meeting of Stockholders on June 23, 2026, with 73,270,239 shares of voting common stock eligible as of the April 24, 2026 record date. Shareholders voted on the election of four Class II directors and the ...
Executive/Board Changes
Candel Therapeutics Updates Employment Agreement with Chief Financial Officer
Neutral
Jun 16, 2026
On June 12, 2026, Candel Therapeutics entered into a new employment agreement with Chief Financial Officer Charles Schoch, formalizing the terms of his ongoing at-will employment. The contract maintains his annual base salary at $468,600, preserve...
Business Operations and StrategyProduct-Related Announcements
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data
Positive
May 15, 2026
On May 15, 2026, Candel Therapeutics held a live investor webcast in conjunction with the American Urological Association 2026 Annual Meeting to review extended follow-up data from its randomized, placebo-controlled phase 3 trial of aglatimagene b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.